J&J wins Arkansas appeal; $1.2bn judgment overturned
This article was originally published in Scrip
Executive Summary
The Arkansas Supreme Court on 20 March overturned a lower court's ruling ordering Johnson & Johnson and its subsidiary Janssen to pay 1.2bn in fines after a jury said the company had defrauded the state's Medicaid program by downplaying and misleading doctors and patients about the risks of diabetes and weight gain with the firm's antipsychotic Risperdal (risperidone).